TPST Valuation
Tempest Therapeutics Inc
$
6.700
- Overview
- Forecast
- Valuation
TPST Relative Valuation
TPST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TPST is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for TPST's competitors is 2.31, providing a benchmark for relative valuation. Tempest Therapeutics Inc Corp (TPST) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
AAPL
Apple Inc
208.760
USD
-1.18%
TSLA
Tesla Inc
341.790
USD
-2.34%
META
Meta Platforms Inc
640.250
USD
-0.01%
WMT
Walmart Inc
98.035
USD
-0.21%
ORCL
Oracle Corp
159.400
USD
-0.68%
AMZN
Amazon.com Inc
206.140
USD
+0.27%
NVDA
NVIDIA Corp
135.490
USD
+0.07%
AVGO
Broadcom Inc
230.610
USD
+0.87%
MSFT
Microsoft Corp
458.860
USD
+1.01%
XOM
Exxon Mobil Corp
106.450
USD
-1.61%
FAQ
Is Tempest Therapeutics Inc (TPST) currently overvalued or undervalued?
Tempest Therapeutics Inc (TPST) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Tempest Therapeutics Inc (TPST) is between to according to relative valuation methord.
What is Tempest Therapeutics Inc (TPST) fair value?
How does TPST's valuation metrics compare to the industry average?
What is the current P/B ratio for Tempest Therapeutics Inc (TPST) as of May 19 2025?
What is the current FCF Yield for Tempest Therapeutics Inc (TPST) as of May 19 2025?
What is the current Forward P/E ratio for Tempest Therapeutics Inc (TPST) as of May 19 2025?